StockNews.com Downgrades Biogen (NASDAQ:BIIB) to Buy

StockNews.com downgraded shares of Biogen (NASDAQ:BIIB – Free Report) from a strong-buy rating to a buy rating in a report released on Wednesday morning. BIIB has been the subject of a number of other research reports. UBS Group cut their target price on shares of Biogen from $234.00 to $202.00 and set a “neutral” rating […]

Leave a Reply

Your email address will not be published.

Previous post SkyView Investment Advisors LLC Cuts Holdings in Oracle Co. (NYSE:ORCL)
Next post First Drive: All-New Dodge Charger Daytona Coupe – Extreme Electric Muscle Car Performance